[1] |
The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis, 1994, 75(3):180-181. doi: 10.1016/0962-8479(94)90004-3.
doi: 10.1016/0962-8479(94)90004-3
URL
|
[2] |
朱莉贞, 严碧涯, 马伟路. 固定剂量复合剂卫非特/卫非宁治疗结核病的临床对照研究. 中华结核和呼吸杂志, 1998, 21(11): 645-647.
|
[3] |
成诗明, 钟球, 郑金凤, 等. 固定剂量复合剂在国家结核病防治规划中的应用研究. 中国防痨杂志, 2007, 29(2): 111-116.
|
[4] |
王倪, 周林, 池俊英, 等. 不同服药方式抗结核固定剂量复合剂的疗效与不良反应分析. 现代预防医学, 2012, 39(23): 6275-6277.
|
[5] |
周林, 王倪, 刘二勇, 等. 5981例肺结核患者服用抗结核固定剂量复合制剂所致肝损伤分析. 中国防痨杂志, 2014, 36(4): 256-259. doi: 10.3969/j.issn.1000-6621.2014.04.007.
doi: 10.3969/j.issn.1000-6621.2014.04.007
|
[6] |
Xu J, Jin H, Zhu H, et al. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. Clin Ther, 2013, 35(2):161-168. doi: 10.1016/j.clinthera.2013.01.003.
doi: 10.1016/j.clinthera.2013.01.003
URL
|
[7] |
中华人民共和国国务院办公厅. 国务院办公厅关于印发全国结核病防治规划(2011-2015年)的通知. 国办发〔2011〕53号. 2011-11-17.
|
[8] |
中华人民共和国国家卫生健康委员会办公厅. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279 号.2020-04-02.
|
[9] |
常婷婷, 常晓杰. 8369例抗结核固定剂量复合制剂应用情况分析. 临床药物治疗杂志, 2021, 19(12): 54-57. doi: 10.3969/j.issn.1672-3384.2021.12.012.
doi: 10.3969/j.issn.1672-3384.2021.12.012
|
[10] |
杨天池, 于梅, 赵敏捷, 等. 固定剂量复合制剂治疗初治活动性肺结核的效果. 中国公共卫生管理, 2010, 26(5): 505-507.
|
[11] |
孔雯, 刘巧. 我省抗结核固定剂量复合制剂使用情况分析. 临床肺科杂志, 2014, 19(7): 1275-1277. doi: 10.3969/j.issn.1009-6663.2014.07.039.
doi: 10.3969/j.issn.1009-6663.2014.07.039
|
[12] |
钱明红, 张淑兰, 单志力, 等. 温州市固定剂量复合制剂在结核病治疗中的使用情况分析. 中国农村卫生事业管理, 2017, 37(4): 425-427. doi: 10.3969/j.issn.1005-5916.2017.04.023.
doi: 10.3969/j.issn.1005-5916.2017.04.023
|
[13] |
Lai JML, Yang SL, Avoi R. Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice. J Glob Infect Dis, 2019, 11(1):2-6. doi: 10.4103/jgid.jgid_50_18.
doi: 10.4103/jgid.jgid_50_18
URL
|
[14] |
中国防痨协会学术工作委员会,《中国防痨杂志》编辑委员会. 抗结核药品固定剂量复合制剂的临床使用专家共识. 中国防痨杂志, 2020, 42(9): 885-893. doi: 10.3969/j.issn.1000-6621.2020.09.001.
doi: 10.3969/j.issn.1000-6621.2020.09.001
|
[15] |
Du X, Li T, Liu X, et al. Health Facilities and Treatment Service Models of the National Tuberculosis Program-China, 2010-2020. China CDC Weekly, 2021, 3(13): 274-278. doi: 10.46234/ccdcw2021.071.
doi: 10.46234/ccdcw2021.071
URL
|
[16] |
Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med, 2018, 24(11):1708-1715. doi: 10.1038/s41591-018-0224-2.
doi: 10.1038/s41591-018-0224-2
URL
|
[17] |
王倪, 黄飞, 赵雁林. 新型冠状病毒肺炎疫情防控经验对结核病防治工作的启示. 中华传染病杂志, 2022, 40(1): 1-5. doi: 10.3760/cma.j.cn311365-20210902-00317.
doi: 10.3760/cma.j.cn311365-20210902-00317
|
[18] |
Tola HH, Tol A, Shojaeizadeh D, et al. Tuberculosis Treatment Non-Adherence and Lost to Follow Up among TB Patients with or without HIV in Developing Countries: A Systematic Review. Iran J Public Health, 2015, 44(1):1-11.
|
[19] |
Xu W, Lu W, Zhou Y, et al. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res, 2009, 9:169. doi: 10.1186/1472-6963-9-169.
doi: 10.1186/1472-6963-9-169
URL
|
[20] |
王倪, 张慧, 张铁娟, 等. 使用电子药盒辅助肺结核患者服药管理的实施情况分析. 中国防痨杂志, 2020, 42(7): 682-686. doi: 10.3969/j.issn.1000-6621.2020.07.008.
doi: 10.3969/j.issn.1000-6621.2020.07.008
|